Asset profile
CytoSorb · Cytosorbents Corp. (CTSO)
- Indication
- cardiac surgery and critical care (including bleeding reduction, vasoplegia, hyperinflammation, heart transplant, sepsis, liver support, ECMO)
- Also known as
- CytoSorb®, hemoadsorption
Company
CTSOCytosorbents Corp.
CTSOCytosorbents Corp.CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads…
On the calendar
Timeline
Newest first.
Sep 30, 2026
07:00 PM
CTSOCytosorbents Corp.CytoSorbents to Present CytoSorb Data at EACTS and ESICM Conferences in October 2026
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT04742764 | Phase 3 | Suspended | Oct 31, 2026 | 135 | 0 of 1 sites in the United States |
| NCT01879176 | Phase 3 | Completed | May 1, 2015 | 46 | 0 of 1 sites in the United States |